Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $7.00

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $5.50.

A number of analysts recently weighed in on the stock. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, December 13th. Barclays increased their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday. Wells Fargo & Company lowered their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Tuesday. Finally, Jefferies Financial Group cut their price objective on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SGMO. Cubist Systematic Strategies LLC bought a new stake in Sangamo Therapeutics in the second quarter worth $67,000. Meritage Portfolio Management grew its stake in shares of Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 6,740 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Sangamo Therapeutics in the 2nd quarter worth approximately $89,000. XTX Topco Ltd increased its position in Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 64,981 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO opened at $1.13 on Tuesday. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The stock has a market cap of $235.77 million, a PE ratio of -1.51 and a beta of 1.15. The stock has a fifty day moving average of $2.14 and a 200-day moving average of $1.22.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. During the same quarter in the previous year, the firm earned ($0.34) EPS. On average, sell-side analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.